INDIGO Trial: Examining IDH-Mutant Low-Grad Gliomas
Panelists discuss how the INDIGO trial results and vorasidenib's approval could shift treatment paradigms for IDH-mutant low-grade gliomas, weighing various clinical, molecular, and patient-specific factors when considering the integration of this novel targeted therapy into individualized treatment plans.
CN24_SS_Glioma_Seg05_INDIGO-Trial
Video Player is loading.
EP: 1.Real-World Clinical Practice: Challenges With Glioma Management
EP: 2.Treatment Approaches for Patients With Oligodendrogliomas and Grade 2 Gliomas
EP: 3.CATNON Trial: Concurrent Versus Adjuvant Temozolomide in Treating WHO Grade 3 Astrocytomas Without 1p/19q Codeletion
EP: 4.IDH Inhibitors in the Treatment of Low-Grade Gliomas
Now Viewing
EP: 5.INDIGO Trial: Examining IDH-Mutant Low-Grad Gliomas
EP: 6.Closing Thoughts and Unmet Needs in Glioma Treatment
- How might the results of the INDIGO trial and the approval of vorasidenib influence treatment decisions for IDH-mutant low-grade gliomas?
- What factors would you consider when evaluating these new treatment options for patients?
Recent Videos
Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer
Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer
Second-Line Treatment for Gastric Adenocarcinoma
Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches
Gastric Adenocarcinoma: Current Treatment Landscape
Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW
Esophageal/Gastric Adenocarcinoma Standard of Care
BESPOKE: Study Design, Efficacy End Points and Methods
Related Content
